Efficacy of Linezolid Versus Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Discitis
Authors:
- Jason M. ConaughtyJCJason M. Conaughty
- Jack ChenJCJack Chen
- Octavio V. MartinezOMOctavio V. Martinez
- Gino ChiappettaGCGino Chiappetta
- Kathleen F. BrookfieldKBKathleen F. Brookfield
- Frank J. EismontFEFrank J. Eismont
- 1 October 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Spine
- Vol. 31 (22) , E830-E832
Abstract
A rabbit model was used to assess the efficacy of linezolid and vancomycin for the treatment of discitis due to methicillin-resistant Staphylococcus aureus (MRSA). Nontreated controls were used for comparison. The purpose of this study was to determine if there was a therapeutic difference between using linezolid and vancomycin in the treatment of MRSA discitis. Vancomycin is currently the gold standard treatment for medical management of MRSA discitis. Linezolid is a relatively new drug that has been approved for treatment of MRSA infections, but currently there is no research demonstrating its efficacy at treating infections of the disc space. Twenty-four rabbits were inoculated with MRSA at two adjacent lumbar disc spaces via an anterior retroperitoneal approach. Six rabbits were to receive only pain medication and to serve as controls. Ten rabbits were assigned to a 5-day course of intravenous vancomycin, and 8 were assigned to a 5-day course of intravenous linezolid. Disc spaces were sent for quantitative culture after the 5-day treatment course. The mean culture growth for the disc spaces was not statistically different between the linezolid treated group and the nontreated controls. While vancomycin treatment did lead to lower bacterial loads when compared with controls, the reduction was not statistically significant. When bacterial counts for the vancomycin group and linezolid group were compared, vancomycin treatment resulted in less bacterial growth. This difference was statistically significant. Linezolid is a clinically attractive alternative to vancomycin due to its mild side effect profile and oral bioavailability. However, in this MRSA discitis model with a short treatment course, vancomycin was superior to linezolid.Keywords
This publication has 16 references indexed in Scilit:
- Linezolid in the Treatment of Osteomyelitis: Results of Compassionate Use ExperienceInfection, 2004
- Linezolid vs Vancomycin *Chest, 2003
- Linezolid penetration into osteo-articular tissuesJournal of Antimicrobial Chemotherapy, 2002
- Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacementJournal of Antimicrobial Chemotherapy, 2002
- Clinical Trial Results with Linezolid, an Oxazolidinone, in the Treatment of Soft Tissue and Postoperative Gram-Positive InfectionsSurgical Infections, 2001
- Linezolid Therapy of Staphylococcus aureus Experimental OsteomyelitisAntimicrobial Agents and Chemotherapy, 2000
- The Effect of Prophylactic Antibiotics on Iatrogenic Intervertebral Disc InfectionsSpine, 1995
- Methicillin-Resistant Staphylococcus aureus in U.S. Hospitals, 1975–1991Infection Control & Hospital Epidemiology, 1992
- Antibiotic Penetration into Rabbit Nucleus PulposusSpine, 1987
- Nutrition of the Intervertebral DiskClinical Orthopaedics and Related Research, 1977